Welcome!

News Feed Item

Stakeholder Perspectives: Innovation within the Biopharma Industry

NEW YORK, March 3, 2014 /PRNewswire/ -- New Reportlinker.com announces that a new market research report is available in its catalogue: Stakeholder Perspectives: Innovation within the Biopharma Industry

http://www.reportlinker.com/p02027811/Stakeholder-Perspectives-Innovation-within-the-Biopharma-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

What does innovation mean within the biopharma industry? How much you spend on R&D? How many products you bring to market? How many New Molecular Entities (NME) you have in research?

Within the biopharma industry, R&D output is at odds with R&D investment. Between 1950 and 2010, the number of new molecules (including both biologics and small molecules) brought to market by the biopharma industry, per billion dollars of R&D expenditure, fell by a factor of 100 in inflation adjusted terms. Innovation, it seems, is getting increasingly expensive while the prospect of blockbuster income to pay for it is getting rarer. Something has to change.

So...what are the issues we need to consider?

- New molecular entity (NME) output is not an accurate reflection of the state of innovation: new ways of measuring innovation within the biopharma industry are needed. Current methods of measuring NME output from either the FDA or EMA provide only a snapshot of what regulatory agencies deem approvable. The industry needs to move beyond NME output as a measure of innovation, taking into account provider, purchaser and user metrics including pipeline activity, clinical success, regulatory approval, patient access, satisfaction of unmet need and overall value to society;

- Collaboration is critical to success: Industry must leverage the experience, skills and insights from a diverse range of stakeholders such as physicians, patients and payers – this is critical to the future of innovation. But collaboration needs to be smart. Biopharma companies must collaborate only when the expected outcome adds value to society, contributes to better patient outcomes and supports commercial goals;

- Companies need to be brave: constantly mining a 'comfort zone' of known approaches leads to complacency and limits innovation. While many believe that all of the 'low hanging fruit' have been taken there is another perspective: that there is plenty of fruit left on the tree and companies just need the bravery and vision to look for them.

This FirstView advisory report – the first in a major new series – provides everyone interested in the dynamics of biopharma innovation with a robust understanding of the issues, opinions and insights that are shaping the current environment, and the events that could lead to a change in the future. Every aspect of the report is informed by expert insight gathered from 60-minute interviews with 16 key opinion leaders (KOLs), payers and senior industry executives from leading companies from across Europe and the US.

Experts share their insights on...

- The impact of innovation within biotechnology over the last 15-20 years- A view of what a world without biologics would have looked like
- The pros and cons of biological therapies
- Where biologics have been best received and where there is still resistance
- The role that industry played, and needs to play, within the 'innovation ecosystem'
- The important and growing roles of key stakeholder groups
- Attitudes toward innovation within industry
- New technologies and innovations that are exciting industry at the moment, and hypotheses about the future of innovation and roles in driving it forward
- This report tackles the pressing innovation issues and questions

What does biopharma innovation mean?

- Where is innovation coming from?
- How can the lessons of the last few decades be used to guide future biopharma innovation?
- What will be the future trends in biopharma innovation?
- How has biopharma innovation been measured in the past, and do new ways of measuring innovation need to be developed?
- What must biopharma companies focus on in order to remain competitive and deliver innovation that is truly valued by society?
- Which companies are currently viewed as being leaders of innovation within the pharmaceutical industry?
- What disruptive technologies and market dynamics are likely to impact the rate of innovation within the biopharma industry?
- What do KOLs, payers and industry stakeholders view as critical for biopharma companies to focus on in order to maintain shareholder returns and deliver customer value?

Whether you work in big pharma, a drug discovery company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment of how we can better cost-effectively develop and bring biopharmaceuticals to the market in a timely manner.

Report Benefits

- Understand and evaluate the current status of innovation within the biopharma industry, including the key drivers and resistors of innovation

- Get up to speed with current thinking on how innovation is measured within the biopharma industry

- Know what potential changes need to be made in terms of how innovation will be assessed in the future

- Understand clinical, payer and industry opinions of current and future market dynamics

- Appreciate what the critical opportunities biopharma companies should be investing in and how these opportunities can be realised

Selected Quotes from the Report

'Innovation [within pharma] is a lot like a fine Swiss watch. There are multiple moving parts but if you take one part out, the watch stops. So every part in that watch is absolutely critical to the functioning of that watch in the same way that every key stakeholder group within the innovation ecosystem has a critical role. Whether it be a payer, a physician, a company, a policy maker, a scientist, etc. They all have a role to play and if they stop playing that role, the system falls over.' Former Head of Innovation, Eli Lilly.

'Collaboration is your key for survival for the future. You cannot always count on the old model of finding solutions inside your own company.' Global Head of External Innovation & Strategic Partnerships, Roche.

'If we had a shorter, faster, more efficient regulatory system, then the cost [and time taken] to complete clinical trials would go down. I think we need to re-think how it could be smarter, more efficient. At the moment, the regulatory system is set up to benefit big pharma, not smaller companies.' Scientific Advisor, Innogen Institute.

'My view is that biopharma companies need to be more receptive to new models of innovation, and that includes more collaborations, more discussions, sharing of data. I'm not a big believer of we [the biopharma industry] are better than everyone else and we know better, so I think that being open to the environment is really important.' Head of Innovation at Merck Serono.

'Do we have a secret sauce [when it comes to innovation]? I don't know. I think it's the willingness to take a little bit of risk in that space. I think understanding that as good as we have been in the past, it wasn't enough. We knew that that landscape was clearly changing and under some great leadership, we were able to move into a completely new system. Good people like to follow good leaders so that's certainly a part of it.' VP Strategy & Operations, Janssen R&D.

'My personal opinion is that the time of the very, very large pharma companies is maybe already over. They're not dynamic enough to react very quickly to changing and dynamic patient needs, so smaller conglomerates of people who throw their expertise into one bucket and do that quickly might win over large pharma companies.' Senior Manager, Boehringer Ingelheim.

Experts interviewed for this report

This report benefits from the considered insight of leading clinicians, payers and senior industry experts. These include:

KOL's with relevant clinical, regulatory, scientific and commercial experience, scientific publications, involvement in clinical trials and their record of presenting at high profile international conferences.

Payers with relevant (and recent) experience of deciding on the reimbursement of expensive biological therapies in areas such as oncology, inflammatory conditions, orphan diseases and infectious diseases.

Senior industry executives with current (or recent) experience in innovation, strategy, business development, licensing, competitive intelligence and long-term planning.

Their names have been kept confidential to provide contributors with a secure forum in which they could share their candid opinions and views.

Key Opinion Leaders

Rheumatologist, UK

Rheumatologist, Germany

Rheumatologist, US

Oncologist, US

Payers

Director, Managed Care Organization

Former Pharmacy Director, Harvard Pilgrim Health

Director, Health Insurance (Germany)

Head of Medicines Management, CCG (UK)

Industry Experts

Former Head of Innovation at Eli Lilly

Senior Manager, Boehringer Ingelheim

Head of Innovation, Merck Serono

Scientific Advisor, Innogen Institute

VP Strategy & Operations, Janssen R&D

Global Head, Innovation & Partnerships, Roche

Two senior executives from a large EU-based biotech firm

Who should read this report, and why?

FirstView's Stakeholder Perspectives: Innovation within the Biopharma Industry is a 'must read' for industry executives working in the areas of innovation strategy, business development & licensing, competitive intelligence, long-term planning, market access, R&D, partnering & alliance management, and emerging markets. Each stakeholder group will be able to use the insight delivered in the report to:

- Review aims, objectives and goals of current innovation strategy, and what (on the basis of the way the market is evolving) will be the critical success factors for future success;

- Reassess business development and licensing needs, aims and objectives to ensure that all future deals are accretive in terms of their ability to deliver innovative products to the market;

- Review external competitor strategies with a view to ensuring internal stakeholders are kept up to speed with market and competitive developments;

- Perform internal scenario analyses of various opportunities (e.g. gene therapy, regenerative medicine and technology opportunities) to see what will be needed to leverage the opportunity, and to understand what potential future business models will be needed;

- Review relationships with payers, asking the question 'are we providing the right data to payers for our innovative products'?

- Review current clinical trial strategies to improve the effectiveness of clinical trials, making them faster, smarter and cheaper, and review regulatory strategies based on increased regulatory hurdles;

- Get a better understanding of what critical attributes are needed in partners when assessing collaborations and joint ventures;

- Engage in portfolio optimisation work in emerging markets to ensure that needs of the market are being addressed by current portfolio; if not, review opportunities to in-license, partner, divest assets.

About FirstView Reports

FirstWord's FirstView Stakeholder Perspectives: Innovation within the Biopharma Industry is the first of a new series of authoritative analyses that focus on the drivers and resistors of innovation within the biopharma industry.

Innovation is the life blood of the industry, yet the cost of developing and bringing new products to market is spiralling. The series will forensically examine and answer fundamental questions such as:

- As the market moves away from blockbusters to 'niche-busters', how can industry and regulators bring new products to market that are not only safe and effective, but also affordable?

- Is the current clinical trials system still fit for purpose, or does industry and the regulators need to develop innovative, more efficient ways of establishing the clinical utility of new medicines?

- Are the advances in personalised medicine already witnessed only the tip of the iceberg, or have we seen all there is to offer in the field of stratified medicine?

- Are biosimilars set to take the market by storm and deliver on the promise of high quality, affordable biologics for all, or will the sector crumble under the weight of its own expectations?

- 'Beyond the Pill.' Do you have a strategy? Do you need one? And how influential will payers be when it comes to the impact of 'beyond the pill' solutions on biopharma revenues?

The pharmaceutical industry is on the verge of significant change. Old biopharma business models are under significant stress, and things need to change. Make sure you understand the potential strategic implications of these upcoming changes with FirstWord's FirstView Reports!

1.Executive summary

2.Research methodology, aims and objectives

3.Innovation within the biopharma industry

3.1.A review and analysis of the defining characteristics of today's biopharma industry, and how they are effecting innovation

3.2.The measurement and benchmarking of innovation within the biopharma industry, and some views on the key drivers and resistors of innovation

4.Key stakeholders in the innovation ecosystem

4.1.Who they are, and what their roles must be in order to drive innovation

4.2.Future perspectives on how each key stakeholder group must learn to work together more closely

5.Opportunities for biopharma companies, both now and in the future

5.1.A review and analysis of some of the key opportunities biopharma companies should be investing in to drive future growth, including 'beyond the pill' strategies, biosimilars, cancer immunotherapy, gene therapy, regenerative medicine, personalised medicine and networks.

6.A scenario-based analysis of potential biopharma futures

6.1An overview of scenarios, and how they can be used to analyse potential future market dynamics

6.2.The critical scenario drives of this report, and how they were devised

6.3.Four potential scenarios, with a robust review of each scenario in terms of its potential implications to the key stakeholders within the innovation ecosystem

6.4.Expert views and insight on the scenarios, and what it could mean for biopharma companies.

7.Concluding remarks

To order this report: Stakeholder Perspectives: Innovation within the Biopharma Industry

http://www.reportlinker.com/p02027811/Stakeholder-Perspectives-Innovation-within-the-Biopharma-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Contact Clare:
[email protected]
US: (339)-368-6001
Intl: +1-339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
"We view the cloud not really as a specific technology but as a way of doing business and that way of doing business is transforming the way software, infrastructure and services are being delivered to business," explained Matthew Rosen, CEO and Director at Fusion, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...